Top Markets
#1 ADO Protocol ADO Protocol +336.33%
#2 Islamic Coin Islamic Coin +155.40%
#3 GoPlus Security GoPlus Security +51.61%
#4 Starpower Starpower +33.70%
#5 GAIB AID GAIB AID +24.67%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.27%
#7 The Black Bull The Black Bull +15.49%
#8 Nockchain Nockchain +14.55%
#9 XMAQUINA XMAQUINA +12.20%
#10 Casper Network Casper Network +11.65%
Coin of the day
ADO Protocol ADO Protocol
Settings
Language
ENGLISH
Currency
USD
Theme
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Rank in Stocks #33297
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Share Price
$0.4264
Last synced: 2022-09-14
Market Cap
$7.93M
Change (1 day)
-16.44%
Change (1 year)
0.00%
Country
US
Trade Caladrius Biosciences, Inc. (CLBS)

Category

Healthcare
P/B ratio for Caladrius Biosciences, Inc. (CLBS)
P/B ratio as of 2026 TTM: 0
According to Caladrius Biosciences, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Caladrius Biosciences, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE